On Feb.10, the U. S. Food and Drug Administration hosted a webinar[1] explaining draft guidance[2] published in December 2021 on the use of digital health technologies, or DHTs, to acquire data in remote clinical trials. [3]DHTs are any system that uses computing platforms, connectivity, software and sensors for health care and related uses. [4]During COVID-19’s emergence, most clinical trials either faced significant challenges or came to a halt as they dealt with site closures, social distancing, quarantines, unattainable protocols, travel restrictions, supply chain disruptions and staff and participants infections.